NCT06238024 (IRIS) is a Phase 2, PHASE3 clinical trial of Tocilizumab in Interleukin-6, sponsored by Suzhou Municipal Hospital of Anhui Province.

Who is sponsoring NCT06238024?

NCT06238024 is sponsored by Suzhou Municipal Hospital of Anhui Province.

What drugs are being tested in NCT06238024?

Interventions in NCT06238024: Tocilizumab, NaCl 0.9% 100ml.

What condition does NCT06238024 study?

NCT06238024 studies Interleukin-6, Ischemic Stroke, Endovascular Treatment.

Is NCT06238024 still recruiting?

NCT06238024 is currently completed. Last updated 25 September 2024.

Last reviewed 2024-09-25 · How we verify

NCT06238024: IRIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Completed Phase 2, PHASE3 Last updated 25 September 2024

What this trial tests

Phase 2, PHASE3 trial testing Tocilizumab in Interleukin-6 in 108 participants. Completed in 22 September 2024.

Timeline

2 February 2024

Primary endpoint
25 June 2024

22 September 2024

Quick facts

Lead sponsor	Suzhou Municipal Hospital of Anhui Province
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	108
Start date	2 February 2024
Primary completion	25 June 2024
Estimated completion	22 September 2024
Sites	1 location across China

Drugs / interventions tested

Tocilizumab (tocilizumab) — full drug profile →
NaCl 0.9% 100ml — full drug profile →

Conditions studied

Interleukin-6 — all drugs for Interleukin-6 →
Ischemic Stroke — all drugs for Ischemic Stroke →
Endovascular Treatment — all drugs for Endovascular Treatment →

Sponsor

Suzhou Municipal Hospital of Anhui Province

Who can join

Adults 18 to 80, any sex, with Interleukin-6 or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases.
Potere N, Bonaventura A, Abbate A. · · 2024 · cited 48× · PMID 39387118 · DOI 10.1161/atvbaha.124.319980
The vascular-immune-neural network: a new pathophysiological paradigm and the dawn of cytoprotection in stroke.
Fang Y, Zhu Z, Zhang JH, Shi FD, et al · · 2025 · cited 2× · PMID 40618510 · DOI 10.1016/j.ebiom.2025.105843
Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial.
Chu X, Lan J, Ma Z, Yin Y, et al · · 2026 · cited 1× · PMID 41687453 · DOI 10.1016/j.ebiom.2026.106167
Unmasking the Hidden Burden: Inflammation and Cardiovascular Disease <i>JAHA</i> Spotlight on the Role of the Immune System in Cardiovascular Health and Disease.
Bartoli-Leonard F, Clark DE, Singhal NS, Nguyen PK. · · 2026 · cited 1× · PMID 41294082 · DOI 10.1161/jaha.125.047298
Interleukin‑6 and ischemic stroke: From mechanisms to clinical prospects (Review).
Wang X, Zhang X, Lin J, Lin P. · · 2026 · PMID 41508947 · DOI 10.3892/mmr.2026.13790

Verify or expand the search:

Other trials of Tocilizumab

Trials testing the same drug.

NCT03787290 — Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder · Phase 2 · suspended
NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
NCT06016517 — Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting

Other Suzhou Municipal Hospital of Anhui Province trials

Trials by the same sponsor.

NCT07372027 — Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care · NA · recruiting
NCT07335471 — Prevention and Management of Cardiovascular and Cerebrovascular Complications in Maintenance Hemodialysis (MHD) Patients · NA · completed
NCT06539260 — Clinical Relationship Between Vitamin D-mediated Th17 and Treg Cells and Parkinson's Disease · EARLY_PHASE1 · completed
NCT07128212 — Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1 · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06238024 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Suzhou Municipal Hospital of Anhui Province
Last refreshed: 25 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06238024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing